Survival Following Heart Transplantation in Patients with Transthyretin Amyloid Cardiomyopathy

s S177 patients who received an axial or centrifugal flow LVAD as compared to those who went directly to transplant. Methods: Ninety-seven patients underwent orthotopic heart transplant between January 2008 and October 2013. We performed a retrospective analysis of post transplant outcomes in patients with and without an isolated continuous flow LVAD as BTT. Patients with a permanent RVAD, pulsatile LVAD, re-transplant or dual-organ transplants were excluded. Eighty four patients were included in this analysis. Results: There was no statistically significant difference in baseline characteristics and post transplant outcomes between the groups. Conclusion: There was no difference in post transplant outcomes in patients bridged to transplant with an LVAD compared to those who went directly to transplant. There appeared to be a trend toward improved survival in the axial flow group and increased incidence of rejection in the centrifugal flow LVAD group. These findings should be further evaluated in future studies. Baseline Characteristics at Time of Transplant Axial Flow VAD n= 40 Centrifugal Flow VAD n= 16 Direct Transplant n= 28 p Age 54.9 ± 11.8 52.5±13.5 54.0±16.3 0.83 Gender (% male, n) 80% (32) 63% (10) 64% (18) 0.25 Race (% Caucasian, n) 53% (21) 69% (11) 57% (16) 0.54 BMI 28.0 ± 5.5 27.7 ± 6.0 26.4 ± 4.2 0.46 Diagnosis (% ICM, n) 35% (14) 38% (6) 36% (10) 0.99 1A Status at time of Transplant 80% (32) 81% (13) 64% (18) 0.28 Duration of LVAD support (days) 380 ± 252 296 ± 258 *** 0.12 Induction therapy 13% (5) 6% (1) 7% (2) 0.67 Post Transplant Outcomes Axial Flow VAD, n= 40 Centrifugal Flow VAD, n= 16 Direct Transplant, n= 28 p Length of stay after transplant (days) 17.6 ± 15.7 20.9 ± 14.6 18.5 ± 9.8 0.74 30 day survival 98% (39) 94% (15) 100% (28) 0.42 1 year survival 98% (39) 88% (14) 93% (26) 0.34 Incidence of rejection in the first year 28% (11) 38% (6) 25% (7) 0.06